drugset / Trial / NCT02112630
Boceprevir in End Stage Renal Disease (ESRD)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the safety and efficacy of triple therapy with pegylated interferon (P-IFN), ribavirin and boceprevir in patients with genotype 1 chronic Hepatitis C Virus (HCV) infection and end stage renal disease (ESRD) on hemodialysis (HD).
Timeline
- Start
- 2013-05
- Primary completion
- 2015-02
- Completion
- 2015-02
Outcome
Outcome not reported
Stopped (Enrollment): “Poor enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Boceprevir | Small molecule | 800 mg | Oral |
| Subject | P-IFN alfa 2a | Unknown | 0.75 ug/kg | — |
| Subject | P-IFN alfa 2b | Unknown | 135 ug/kg | — |
| Subject | Ribavirin | Small molecule | 200 mg | Oral |